DOCSLIB.ORG

Laws and Regulations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laws and Regulations E/NL. 1959/52 2 December 1959 UNITED NATIONS ENGLISH ONLY LAWS AND REGULATIONS PROMULGATED TO GIVE EFFECT TO THE PROVISIONS OF THE CONVENTION OF 13 JULY 1931 FOR LIMITING THE MANUFACTURE AND REGULATING THE DISTRIBUTION OF NARCOTIC DRUGS, AS AMENDED BY THE PROTOCOL OF 11 DECEMBER 1946 BAHRAIN Communicated by the Government of the United Kingdom of Great Britain and Northern Ireland NOTE BY THE SECRETARY-GENERAL-In accordance with Article 21 of the Convention of 13 July 1931 for Limiting the Manufacture and Regulating the Distribution of Narcotic Drugs, as amended by the Protocol of 11 December 1946, the Secretary-General has the honour to communicate the following legislative text. NOTICE The following Regulation, made by me and allowed by Her Majesty's Principal Secretary of State for Foreign Affairs, is published for general information. M.C.G. MAN Her Majesty's Acting Political Resident in the Persian Gulf Bahrain, July 2, 1959. Queen's Regulation made under Article 82 of the Bahrain Orders, 1952 to 1956 No. 1 of 1959 THE BAHRAIN DANGEROUS DRUGS REGULATION, 1959 1. The Bahrain Control of Dangerous Drugs Ordinance, 1959, an English translation of which is annexed hereto, and which has been given the force of law in Bahrain by Order of His Highness the Ruler of Bahrain, shall apply from the date hereof to all persons subject to the Bahrain Orders, 1952 to 1956, except the Medical Services of Her Majesty's Armed Forces. 2. Any such person found guilty of an offence against the said Regulations shall be liable to the penalties therein prescribed. 3. The Bahrain Dangerous Drugs Regulation, 1955 (No. 2 of 1955)^ is hereby repealed, but this repeal shall not interfere with the prosecution of any offence committed against any provision of that Regulation. 4. This Regulation may be cited as "The Bahrain Dangerous Drugs Regulation, 1959". M.C.G. MAN Her Majesty's Acting Political Resident in the Persian Gulf Bahrain, July 2, 1959 Allowedt SELWYN LLOYD Her Majesty's Principal Secretary of State for Foreign Affairs 1/ Note by"the Secretariatt E/NL.1956/97 . - 2 - ANNEX THE BAHRAIN CONTROL OF DANGEROUS DRUGS ORDINANCE, 1959 1. (1) No person or body of persons shall procure, be in possession of, sell or otherwise supply any dangerous drugs in Bahrain or its Dependencies except the Medical Department of the Government of Bahrain (hereinafter called the Government), any State Hospital or State Dispensary, the American Mission Hospital, the Bahrain Petroleum Company Hospital and such other persons or bodies of persons as may be authorized from time to time to be in possession of or to sell or otherwise to supply such drugs under licence from the Health Department of the Government. (2) Nothing in this Section shall prohibit individuals from having in their possession such quantities of drugs as may be prescribed in good faith for their personal use for medical reasons by a medical practitioner who has been approved by the Government for the purpose. (3) No medical practitioner shall issue a prescription for dangerous drugs to any person for any purpose other than bona fide medical treatment. 2. All persons and bodies of persons authorized under Section 1 of this Ordinance to be in possession of or to sell or otherwise supply dangerous drugs shall maintain a register in the form set out in Schedule A to this Ordinance and enter therein in chronological sequence true particulars with respect to every quantity of any drug or preparation supplied. In this book shall be recorded the date on which the drug was received, the name and address of the person or firm from whom it was obtained, the amount obtained and the form ij which it was obtained and, with respect to the supply of any such drug, the date on which the trans• action was effected, the name and address of the person or firm supplied, the authority of such person or firm supplied to be in possession, the amount of drug supplied and the form in which such drug was supplied. 3. Entries in the register, which shall at all reasonable times be open to inspection by an authorized representative of the Health Department of the Government, shall be made on the day on which the drug is received or on which the transaction with respect to the supply of the drug takes place or, if that is not reasonably practicable, oh the next day following the said day. 4. No person or body of persons shall import into or export from Bahrain and its Dependencies any dangerous drugs without the written authority of the Director of Customs which will be given only on the production to him of: (a) a declaration made by the importer or exporter setting out in detail the descriptions and quantities of the dangerous drugs to be imported or exported, and (b) in the case of any of the drugs listed in Schedule B hereto, a signed copy of an import or export licence issued by Her Britannic Majesty's Political Agent at Bahrain in respect of the drugs. 5. (l) Any person who within Bahrain and its Dependencies aids, counsels or procures the commission in any place outside Bahrain and its Dependencies of any offence punishable under the provisions of any' law in force in such place and providing for the control or regulation of the manufacture, sale, possession, use, export or import of dangerous drugs shall be guilty of an offence against this Ordinance. (2) For the purpose of prosecution under the preceding sub-section the Court may receive in evidence a certificate purporting to be issued by or on behalf of the Government of any place outside Bahrain and stating that any law mentioned in the said certificate is a law providing for the control or regulation in such place of the manufacture, sale, possession, use, export or import of dangerous drugs and any statement in any such certificate as to the effect of the law mentioned in the certificate or any statement in any such certificate that any facts constitute an offence against the law shall be conclusive unless the contrary is proved to the satisfaction of the Court. - 3 - 6. No person or body of persons shall attempt to do or aid any other person or body of persons in doing anything which is an offence under this Ordinance. 7. Any person found guilty of an offence under this Ordinance shall be liable to imprisonment not exceeding three years or to a fine not exceeding Rs.5,000 or to both, and any dangerous drugs and receptacles and things in relation to which or to the contents of which any offence against this Ordinance has been committed, shall be liable to forfeiture. 8. The expression "dangerous drugs" used in this Ordinance means the drugs listed in Schedules B and C hereto, but does not include the preparations listed in Schedule D hereto. 9. The Bahrain (Control of Dangerous Drugs) Regulations 1374 (1954) are hereby repealed but this repeal shall not interfere with the prosecution of any offence committed thereunder prior to the date of this repeal. 10. This Ordinance may be cited as "The Bahrain Control of Dangerous Drugs Ordinance, 1959", and shall come into force on the second day of July, 1959. SCHEDULE A Form of Register PART I (Entries to be made in case of drugs or preparations obtained) The class of drugs and preparations to which the entries relate to be specified at the head of each page of the Register. Name Address Date on which Form in which Amount obtained supply received Of pei'so n or firm obtained from wllor a obtained PART II (Entries to be made in case of drugs or preparations supplied) The class of drugs and preparations to which the entries relate to be specified at the head of each page of the Register. Name Address Authority of Date on which person or firm Amount Form in which transaction Of person or supplied to be supplied supplied was effected firm supplied in possession - 4 - SCHEDULE B FART I Raw opium; Prepared opium; Coca leaves; Cannabis (Indian hemp); Cannabis resin and preparations whose basis is a resin of cannabis. PART II Medicinal opium; Any extract or tincture of cannabis (Indian hemp) and any preparation, not being a preparation capable of external use only, made from'extract or tincture of cannabis; Morphine and its salts, and any solution or dilution of morphine or its salts in an inert substance whether liquid or solid containing any proportion of morphine, and any preparation, admixture, extract or other substance (not being such a solution or dilution as aforesaid) containing not less than one-fifth of one per cent of morphine (calculated in respect, of anhydrous morphine); Cocaine (including synthetic cocaine) and ecgonine and their respective salts, and any solution or dilution of cocaine or its salts in an inert substance, whether liquid or solid, containing any proportion of cocaine, and any preparation, admixture, extract or other substance (not being such a solution or dilution as aforesaid) containing not less than one-tenth of one per cent of cocaine or any proportion of ecgonine; Ethylmorphine (also known as dionine) and methylmorphine (also known as codeine) and their respective salts and any preparation, admixture or other substance (except syrupus Codeinae Phosphatis B.P.C. 1934 or 1949) containing any proportion of ethylmorphine or methylmorphine associated with any inert substance whether solid or liquid, and any preparation, admixture or other substance containing more than 2.5 per cent of ethylmorphine or methylmorphine (calculated as pure drug) associated with any other medicinal substance.
Load more

Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • Hydromorphone
    Hydromorphone WHAT IS HYDROMORPHONE? sedation, and reduced anxiety. It may also cause Hydromorphone belongs to a class of drugs mental clouding, changes in mood, nervousness, called “opioids,” which includes morphine. It and restlessness. It works centrally (in the has an analgesic potency of two to eight times brain) to reduce pain and suppress cough. greater than that of morphine and has a rapid Hydromorphone use is associated with both onset of action. physiological and psychological dependence. WHAT IS ITS ORIGIN? What is its effect on the body? Hydromorphone is legally manufactured and Hydromorphone may cause: distributed in the United States. However, • Constipation, pupillary constriction, urinary retention, users can obtain hydromorphone from nausea, vomiting, respiratory depression, dizziness, forged prescriptions, “doctor-shopping,” impaired coordination, loss of appetite, rash, slow or theft from pharmacies, and from friends and rapid heartbeat, and changes in blood pressure acquaintances. What are its overdose effects? What are the street names? Acute overdose of hydromorphone can produce: Common street names include: Severe respiratory depression, drowsiness • D, Dillies, Dust, Footballs, Juice, and Smack progressing to stupor or coma, lack of skeletal muscle tone, cold and clammy skin, constricted What does it look like? pupils, and reduction in blood pressure and heart Hydromorphone comes in: rate • Tablets, capsules, oral solutions, and injectable Severe overdose may result in death due to formulations respiratory depression. How is it abused? Which drugs cause similar effects? Users may abuse hydromorphone tablets by Drugs that have similar effects include: ingesting them. Injectable solutions, as well as • Heroin, morphine, hydrocodone, fentanyl, and tablets that have been crushed and dissolved oxycodone in a solution may be injected as a substitute for heroin.
    [Show full text]
  • Thieme: Pharmakologie Und Toxikologie
    627 Sachverzeichnis Vorbemerkung: Im Text des Buches sind für Wirkstoffe immer die internationalen Freinamen benutzt. Im Register sind die Handels- namen mit ௡ gekennzeichnet. Die Handelsnamen sind in den Tabellen „Notwendige Wirkstoffe“ aufgelistet. A Acetyldigoxin 149 Adenosin 139, 163 – Struktur 145 – als Antiarrhythmikum 162 Abacavir 532, 534 Acetylierer, langsamer 59 – Schmerzempfindung 289 Abarelix 399f Acetylsalicylsäure 310, 314ff – Struktur 139 Abatacept 331 – bei akutem rheumatischen Fieber 324 Adenosindesaminase 462 – bei rheumatoider Arthritis 322 – bei Angina pectoris 182 Adenosindiphosphat 139 ABC-Transporter 30 – Anwendung 314 Adenosinmonophosphat, zyklisches 99f Abciximab 183, 209 – bei Herzinfarkt 184 Adenosin-Nukleotid 139 – Thrombozytenaggregationshemmung – Kontraindikation 316 Adenosin-Rezeptor 139 207 – Metabolismus 315 Adenosintriphosphat 139 Abführmittel-Colon 246 – bei Migräne 307 – Schmerzempfindung 289 Abhängigkeit 49 – Nebenwirkung 315 – als Überträgersubstanz 139 – Hypnotika 363 – Pharmakokinetik 314f Adenylatcyclase 8, 100 Abilify௡ 346 – Re-Infarkt-Prophylaxe 184 Adermin 271 Absence – bei Schlaganfall 186 Adevofir-dipivoxil bei Hepatitis B 253 – Antiepileptikawahl 375 – Schmerztherapie, Stufenschema 305 ADH (antidiuretisches Hormon) s. Adiu- – pyknoleptische, Antiepileptikawahl – Schwangerschaft 316 retin 375 – Struktur 315 Adhäsionsprotein 333 Absorption s. Resorption – Thromboseprophylaxe 209 ADHS (Aufmerksamkeits-Defizit/Hyper- Abstillen 404 – Thrombosetherapie 209 aktivitäts-Syndrom) 362 Acamprosat bei
    [Show full text]
  • Federal Register/Vol. 84, No. 26/Thursday, February 7, 2019/Notices
    2570 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices National Fire Protection Association Register pursuant to Section 6(b) of the Morrissette Drive, Springfield, Virginia (‘‘NFPA’’) has filed written notifications Act on October 22, 2018 (83 FR 53297). 22152. simultaneously with the Attorney Suzanne Morris, SUPPLEMENTARY INFORMATION: General and the Federal Trade The Commission disclosing additions or Chief, Premerger and Division Statistics Unit, Attorney General has delegated his changes to its standards development Antitrust Division. authority under the Controlled activities. The notifications were filed [FR Doc. 2019–01489 Filed 2–6–19; 8:45 am] Substances Act to the Administrator of for the purpose of extending the Act’s BILLING CODE 4410–11–P the Drug Enforcement Administration provisions limiting the recovery of (DEA), 28 CFR 0.100(b). Authority to antitrust plaintiffs to actual damages exercise all necessary functions with under specified circumstances. DEPARTMENT OF JUSTICE respect to the promulgation and implementation of 21 CFR part 1301, Specifically, NFPA has provided an Drug Enforcement Administration updated and current list of its standards incident to the registration of development activities, related technical [Docket No. DEA–392] manufacturers, distributors, dispensers, committee and conformity assessment importers, and exporters of controlled activities. Information concerning NFPA Bulk Manufacturer of Controlled substances (other than final orders in regulations, technical committees,
    [Show full text]
  • 1 Impact of Opioid Agonists on Mental Health in Substitution
    Impact of opioid agonists on mental health in substitution treatment for opioid use disorder: A systematic review and Bayesian network meta-analysis of randomized clinical trials Supplementary Table 1_ Specific search strategy for each database The following general combination of search terms, Boolean operators, and search fields were used where “*” means that any extension of that word would be considered: Title field [opium OR opiate* OR opioid OR heroin OR medication assisted OR substitution treatment OR maintenance treatment OR methadone OR levomethadone OR buprenorphine OR suboxone OR (morphine AND slow) OR diamorphine OR diacetylmorphine OR dihydrocodeine OR hydromorphone OR opium tincture OR tincture of opium OR methadol OR methadyl OR levomethadyl] AND Title/Abstract field [trial* OR random* OR placebo] AND All fields [depress* OR anxiety OR mental] Wherever this exact combination was not possible, a more inclusive version of the search strategy was considered. Database Search Strategy Ovid for EBM Reviews - Cochrane Central Register of (opium or opiate$ or opioid or heroin or medication Controlled Trials August 2018; Embase 1974 to assisted or substitution treatment or maintenance September 07, 2018; MEDLINE(R) and Epub Ahead treatment or methadone or levomethadone or of Print, In-Process & Other Non-Indexed Citations buprenorphine or suboxone or (morphine and slow) or and Daily 1946 to September 07, 2018 diamorphine or diacetylmorphine or dihydrocodeine or hydromorphone or opium tincture or tincture of opium or methadol or methadyl
    [Show full text]
  • Chapter 329 [New] Uniform Controlled Substances Act
    CHAPTER 329 [NEW] UNIFORM CONTROLLED SUBSTANCES ACT Part I. General Provisions Section 329-1 Definitions 329-2 Hawaii advisory commission on drug abuse and controlled substances; number; appointment 329-3 Annual report 329-4 Duties of the commission Part II. Standards and Schedules 329-11 Authority to schedule controlled substances 329-12 Nomenclature 329-13 Schedule I tests 329-14 Schedule I 329-15 Schedule II tests 329-16 Schedule II 329-17 Schedule III Tests 329-18 Schedule III 329-19 Schedule IV tests 329-20 Schedule IV 329-21 Schedule V tests 329-22 Schedule V 329-23 Republishing and distribution of schedules Part III. Regulation of Manufacture, Distribution, Prescription, and Dispensing of Controlled Substances 329-31 Rules 329-31.5 Clinics 329-32 Registration requirements 329-33 Registration 329-34 Revocation and suspension of registration 329-35 Order to show cause 329-36 Records of registrants 329-37 Filing requirements 329-38 Prescriptions 329-39 Labels 329-40 Methadone treatment programs Part IV. Offenses and Penalties 329-41 Prohibited acts B-penalties 329-42 Prohibited acts C-penalties 329-43 Penalties under other laws 329-43.5 Prohibited acts related to drug paraphernalia Amended 0612 1 329-44 Notice of conviction to be sent to licensing board, department of commerce and consumer affairs 329-45 Repealed 329-46 Prohibited acts related to visits to more than one practitioner to obtain controlled substance prescriptions 329-49 Administrative penalties 329-50 Injunctive relief Part V. Enforcement and Administrative Provisions 329-51 Powers of enforcement personnel 329-52 Administrative inspections 329-53 Injunctions 329-54 Cooperative arrangements and confidentiality 329-55 Forfeitures 329-56 Burden of proof; liabilities 329-57 Judicial review 329-58 Education and research 329-59 Controlled substance registration revolving fund; established Part VI.
    [Show full text]
  • Hydromorphone and Morphine Are Not the Same Drug!
    HYDROmorphone and Morphine are not the same drug! HYDROmorphone and morphine are deemed high risk/high alert medications. An Independent Double Check (IDC) must be done to avoid errors when administering all high risk drugs. Please refer to Clinical Practice Standard 1-20-6-3-260. HYDROmorphone and morphine need to knows: HYDROmorphone is 5 times more potent than morphine! (e.g., 1 mg of HYDROmorphone PO is equivalent to 5 mg of morphine PO) When administered via the subcutaneous route, these drugs are twice as strong! Therefore when converting between oral and subcutaneous routes half the dose. (10 mg of oral morphine = 5 mg of subcutaneous morphine) HYDROmorphone and morphine: The name game. Both drugs are used in the management of moderate to severe pain. HYDROmorphone and morphine come in different brand names and formulations. HYDROmorphone = Dilaudid (Injectable), Jurnista (SR), HYDROmorph Contin (SR) Morphine = Morphine Sulphate (Injectable), MS-IR, M.O.S. (Liquid/Tablet/SR), M-Eslon (SR), Statex (Liquid/Tablet/Supp.), Doloral (Liquid), MS Contin (SR), Kadian (SR) (SR=Slow Release CAP) *As per NH, use the generic names (NOT THE BRAND NAME), of these drugs in your documentation. Common side effects: 3 ‘B’s of opioid prescribing: Common: Nausea, Vomiting, Constipation, Sedation, Syncope, Xerostomia (Dry Mouth), If your client is on an opioid: Delirium, Restlessness, Urinary Retention. Do they have a Breakthrough? Less Common: Respiratory Depression, Do they have something for Barfing? Opioid-Induced Neurotoxicity, Myoclonus, Do they have something for their Bowels? Pruritis (itching). Opioid induced neurotoxicity: What does it look like? Opioid induced neurotoxicity is the result of a build up of toxic opioid metabolites in the blood stream.
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • List of Narcotic Drugs Under International Control
    International Narcotics Control Board Yellow List Annex to Forms A, B and C 59th edition, July 2020 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, r etaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. V.20-03697 (E) *2003697* Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in the form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention as well as intermediate opiate raw materials; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention.
    [Show full text]
  • Do You Know... Methadone
    Do You Know... Street names: juice, meth (also used to refer to methamphetamines) What is it? Methadone belongs to the opioid family of Methadone drugs. It is used most commonly to treat addiction to other opioid drugs such as heroin, oxycodone (e.g., Percodan, Percocet), fentanyl (e.g., Duragesic, Sublimaze) and hydromorphone (e.g., Dilaudid). Methadone is a synthetic opioid, which means that it is made from chemicals in a lab. Methadone was developed in Germany during the Second World War and was first used to provide pain relief. Methadone maintenance treatment, which prevents opioid withdrawal and reduces or eliminates drug cravings, was first developed in the 1960s. For many years, Canadian reg- ulations around the prescription of methadone were so restrictive that few doctors offered the treatment. People who wanted methadone treatment often had to wait months or years. 1/4 © 2003, 2011, 2012 CAMH | www.camh.ca In the 1990s, the need to reduce the harm of drug use with medical care, improves the chances of having a was more clearly recognized, and changes were made healthy baby. There are no known long-term effects of to make it easier for doctors to provide methadone methadone on the baby. treatment. People who inject opioid drugs regularly, and who are Methadone maintenance is not a “cure”: it is a treatment. HIV- or hepatitis C–positive, are enrolled in methadone Through treatment, people who are addicted to opioids treatment to help protect their health. Methadone receive the medical and social support they need to treatment also helps to prevent these infections from stabilize and improve their lives.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • Hydromorphone Hydrochloride) CS-II WARNING: DILAUDID ORAL LIQUID and DILAUDID TABLETS CONTAIN HYDROMORPHONE, WHICH IS a POTENT SCHEDULE II CONTROLLED OPIOID AGONIST
    DILAUDID® ORAL LIQUID and DILAUDID® TABLETS (hydromorphone hydrochloride) CS-II WARNING: DILAUDID ORAL LIQUID AND DILAUDID TABLETS CONTAIN HYDROMORPHONE, WHICH IS A POTENT SCHEDULE II CONTROLLED OPIOID AGONIST. SCHEDULE II OPIOID AGONISTS, INCLUDING MORPHINE, OXYMORPHONE, OXYCODONE, FENTANYL, AND METHADONE, HAVE THE HIGHEST POTENTIAL FOR ABUSE AND RISK OF PRODUCING RESPIRATORY DEPRESSION. ALCOHOL, OTHER OPIOIDS AND CENTRAL NERVOUS SYSTEM DEPRESSANTS (SEDATIVE-HYPNOTICS) POTENTIATE THE RESPIRATORY DEPRESSANT EFFECTS OF HYDROMORPHONE, INCREASING THE RISK OF RESPIRATORY DEPRESSION THAT MIGHT RESULT IN DEATH. DESCRIPTION Proprietary name: DILAUDID ORAL LIQUID Established name: hydromorphone hydrochloride Route of administration: ORAL (C38288) Active ingredients (moiety): hydromorphone hydrochloride (hydromorphone) # Strength Form Inactive ingredients 1 5 MILLIGRAM LIQUID purified water, methylparaben, propylparaben, sucrose, glycerin, sodium (C42953) metabisulfite Proprietary name: DILAUDID TABLETS Established name: hydromorphone hydrochloride Route of administration: ORAL (C38288) Active ingredients (moiety): hydromorphone hydrochloride (hydromorphone) # Strength Form Inactive ingredients 1 2 MILLIGRAM TABLET D&C red #30 Lake dye, D&C yellow #10 Lake dye, lactose, magnesium (C42998) stearate, sodium metabisulfite 2 4 MILLIGRAM TABLET D&C yellow #10 Lake dye, lactose, magnesium stearate, sodium metabisulfite (C42998) 3 8 MILLIGRAM TABLET lactose anhydrous, magnesium stearate, sodium metabisulfite (C42998) DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid analgesic. The chemical name of DILAUDID (hydromorphone hydrochloride) is 4,5α-epoxy-3- hydroxy-17-methylmorphinan-6-one hydrochloride. The structural formula is: M.W. 321.8 Each 5 mL (1 teaspoon) of DILAUDID ORAL LIQUID contains 5 mg of hydromorphone hydrochloride. In addition, other ingredients include purified water, methylparaben, propylparaben, sucrose, and glycerin. DILAUDID ORAL LIQUID may contain traces of sodium metabisulfite.
    [Show full text]